BioStem Technologies to Host Third Quarter 2025 Financial Results Conference Call on November 13, 2025

BioStem Technologies, Inc. (OTC: BSEM), a prominent player in the MedTech sector, is set to announce its financial results for the third quarter of 2025 on Thursday, November 13, 2025. Following the results release, the company will host a conference call and webcast at 4:30 PM ET. During this event, CEO Jason Matuszewski and CFO Brandon Poe will provide an overview of the company's performance during the quarter. Interested parties can register for the webcast and access the call via specific toll-free numbers and a dedicated linkage.

Based in Pompano Beach, Florida, BioStem Technologies specializes in the development, production, and commercialization of placental-derived products aimed at advancing wound care. The company is recognized for its innovative approach, particularly the proprietary BioREtain® processing method, which is designed to preserve the natural properties and structural integrity of perinatal tissues while maximizing growth factor retention. This technology underscores the company’s commitment to enhancing the effectiveness of regenerative therapies.

BioStem's commitment to quality is evidenced by its accreditation from the American Association of Tissue Banks (AATB), along with adherence to current Good Tissue Practices (cGTP) and current Good Manufacturing Processes (cGMP). Their product line includes notable brands such as AmnioWrap2™, VENDAJE®, VENDAJE AC®, and VENDAJE OPTIC®, all processed at their FDA-registered and AATB-accredited facility.

For those wishing to stay updated on BioStem's innovations and corporate news, the company encourages sign-ups for its email distribution list and engagement through social media channels. With a focus on transformational healthcare solutions, BioStem continues to be an essential player in regenerative medicine.

As BioStem Technologies, Inc. (OTC: BSEM) approaches its third quarter 2025 financial results announcement slated for November 13, 2025, investors should adopt a discerning, yet optimistic approach. The company operates within a rapidly evolving MedTech sphere, focusing on placental-derived products for advanced wound care – a niche market with significant growth potential.

Key factors to consider when evaluating BioStem’s upcoming results include the performance and market adoption of its proprietary BioREtain® processing technology, which has the potential to give the company a competitive edge. As the global demand for effective wound care solutions continues to rise, driven by an aging population and an increase in chronic conditions, BioStem is well-positioned if its products demonstrate clinical efficacy and safety that meet healthcare providers’ demands.

During the conference call, CEO Jason Matuszewski and CFO Brandon Poe will likely highlight operational updates and revenue growth metrics. Investors should listen for insights into product portfolio performance, including existing brands like AmnioWrap2™ and VENDAJE®, alongside any new product launches or approvals. Additionally, information regarding supply chain stability, regulatory approvals, and partnerships can inform future growth prospects and risk assessments.

Currently, with BioStem’s stock trading on the OTC market, the valuation may remain volatile, influenced by market sentiment and investor perception. It’s essential for investors to assess the company’s fundamentals and growth storyline against broader MedTech trends.

In summary, while there is potential upside in BioStem Technologies, any investment decision should be made with an understanding of the associated risks and market conditions. Following the earnings call and subsequent analysis will be crucial to determining the trajectory of the company's stock and assessing its positioning within the competitive landscape.